This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum

Early Bird Price ends in:

  • 00
  • 00
  • 00
  • 00
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

Arthur Pappas
CEO & Managing General Partner at Pappas Capital


Art is an experienced entrepreneur and venture capital investor, and former pharmaceutical and biotechnology industry executive. He founded Pappas Capital in 1994, and over the past twenty-nine years the firm has managed more than $800 million in capital and invested in 90 portfolio companies.

Art currently serves as a director for Allievex and Sorriso Pharmaceuticals, and as an observer for Glycomine and CuraSen. Prior to founding Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals, as a director for Aura Biosciences, Reneo Pharmaceuticals, Afferent Pharmaceuticals, Arix Bioscience, Chimerix, TYRX, Quintiles Transnational Corp., Syntonix Pharmaceuticals, LEAD Therapeutics and Embrex; and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, Kezar Life Sciences, Milestone Pharmaceuticals and Plexxikon.

Art holds various director, trustee and advisor positions for the North Carolina Biotechnology Center, the Biotechnology Innovation Organization (BIO), The Wistar Institute, the Ronald McDonald House of the Triangle, and the Duke Cancer Institute. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne JFK Special Warfare Center. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.

Agenda Sessions

  • Deals, breakthrough innovation, and partnering for biotech's next generation